Carbapenem-resistant pseudomonas aeruginosa bacteremia: Risk factors for mortality and microbiologic treatment failure

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Buehrle, Deanna J ^a   Shields, Ryan K ^a,b   Clarke, Lloyd G ^c   Potoski, Brian A ^c   Clancy, Cornelius J ^a,b,d   Hong Nguyen, M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Carbapenem resistance; Mortality; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CHARLSON COMORBIDITY INDEX; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MONOTHERAPY; MORTALITY RATE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; BACTEREMIA; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 85009238117     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01243-16     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62:1-7.
2. Maechler F, Pena Diaz LA, Schroder C, Geffers C, Behnke M, Gastmeier P. 2015. Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection 43:163-168. https://doi.org/10.1007/s15010-014-0701-6.
3. Hasanin A, Eladawy A, Mohamed H, Salah Y, Lotfy A, Mostafa H, Ghaith D, Mukhtar A. 2014. Prevalence of extensively drug-resistant gram negative bacilli in surgical intensive care in Egypt. Pan Afr Med J 19:177.
4. Lyman M, Walters M, Lonsway D, Rasheed K, Limbago B, Kallen A. 2015. Notes from the field: carbapenem-resistant Enterobacteriaceae producing OXA-48-like carbapenemases-United States, 2010-2015. MMWR Morb Mortal Wkly Rep 64:1315-1316. https://doi.org/10.15585/mmwr.mm6447a3.
5. Muscarella LF. 2014. Risk of transmission of carbapenem-resistant Enterobacteriaceae and related "superbugs" during gastrointestinal endoscopy. World J Gastrointest Endosc 6:457-474. https://doi.org/10.4253/wjge.v6.i10.457.
6. Enfield KB, Huq NN, Gosseling MF, Low DJ, Hazen KC, Toney DM, Slitt G, Zapata HJ, Cox HL, Lewis JD, Kundzins JR, Mathers AJ, Sifri CD. 2014. Control of simultaneous outbreaks of carbapenemase-producing enter-obacteriaceae and extensively drug-resistant Acinetobacter baumannii infection in an intensive care unit using interventions promoted in the Centers for Disease Control and Prevention 2012 carbapenemase-resistant Enterobacteriaceae Toolkit. Infect Control Hosp Epidemiol 35: 810-817. https://doi.org/10.1086/676857.
7. Zilberberg MD, Shorr AF. 2013. Secular trends in gram-negative resis-tance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 34:940-946. https://doi.org/10.1086/671740.
8. Huang TD, Berhin C, Bogaerts P, Glupczynski Y; multicentre study group. 2013. Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium. J Antimicrob Chemother 68:1832-1837. https://doi.org/10.1093/jac/dkt096.
9. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58: 4443-4451. https://doi.org/10.1128/AAC.00099-14.
10. Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. 2015. Tigecycline activity tested against carbapenem-resistant Entero-bacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Diagn Microbiol Infect Dis 83:183-186. https://doi.org/10.1016/j.diagmicrobio.2015.06.011.
11. Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Lephart PR, Chopra T, Hayakawa K, Martin ET, Abreu-Lanfranco O, Dhar S, Kaye KS, Marchaim D. 2012. Retrospective evaluation of colistin versus tigecycline for the treatment of Acineto-bacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 40:983-987. https://doi.org/10.1016/j.ajic.2011.12.014.
12. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 13 September 2016. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteria-ceae infections. Clin Infect Dis https://doi.org/10.1093/cid/ciw636.
13. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. 2014. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. J Antimicrob Chemother 69:1804-1814. https://doi.org/10.1093/jac/dku048.
14. Bonomo RA, Szabo D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43(Suppl 2):S49-S56. https://doi.org/10.1086/504477.
15. CLSI. 2014. Performance standards for antimicrobial susceptibility test; 24th informational supplement. M100-S24. CLSI, Wayne, PA.
16. Tsai MH, Wu TL, Su LH, Lo WL, Chen CL, Liang YH, Chiu CH. 2014. Carbapenem-resistant-only Pseudomonas aeruginosa infection in patients formerly infected by carbapenem-susceptible strains. Int J Anti-microb Agents 44:541-545. https://doi.org/10.1016Zj.ijantimicag.2014.07.022.
17. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
18. Peña C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez F, Tubau F, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases REIPI. 2012. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 56:1265-1272. https://doi.org/10.1128/AAC.05991-11.
19. Tam VH, Chang KT, La Rocco MT, Schilling AN, Mc Cauley SK, Poole K, Garey KW. 2007. Prevalence, mechanisms, and risk factors of carbap-enem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 58:309-314. https://doi.org/10.1016/j.diagmicrobio.2007.05.006.
20. Joo EJ, Kang CI, Ha YE, Kang SJ, Park SY, Chung DR, Peck KR, Lee NY, Song JH. 2011. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist 17:305-312. https://doi.org/10.1089/mdr.2010.0170.
21. Lee CH, Su TY, Ye JJ, Hsu PC, Kuo AJ, Chia JH, Lee MH. 27 June 2015. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. J Microbiol Immunol Infect https://doi.org/10.1016/j.jmii.2015.06.003.
22. Suárez C, Peña C, Gavaldà L, Tubau F, Manzur A, Dominguez MA, Pujol M, Gudiol F, Ariza J. 2010. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int J Infect Dis 14(Suppl 3):e73-e78. https://doi.org/10.1016/j.ijid.2009.11.019.
23. Jeong SJ, Yoon SS, Bae IK, Jeong SH, Kim JM, Lee K. 2014. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Diagn Microbiol Infect Dis 80:130-135. https://doi.org/10.1016/j.diagmicrobio.2014.07.003.
24. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. 2015. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60:1295-1303.
25. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, Es-chenauer GA, Potoski BA, Nguyen MH. 2012. Epidemiology, Clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 7:e52349. https://doi.org/10.1371/journal.pone.0052349.
26. Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, Toyoda Y, Pilewski JM, Crespo M, Pasculle AW, Clancy CJ, Nguyen MH. 2011. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 70:246-252. https://doi.org/10.1016/j.diagmicrobio.2010.12.023.
27. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M. 2013. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13: 2619-2633. https://doi.org/10.1111/ajt.12424.
28. Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A; Spanish Group for the Study of Pseudomonas; Spanish Network for Research in Infectious Diseases. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54: 846-851. https://doi.org/10.1128/AAC.00834-09.
29. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D beta-lactamases. J Biol Chem 288:27960-27971. https://doi.org/10.1074/jbc.M113.485979.
30. Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. An-timicrob Agents Chemother 60:3227-3231. https://doi.org/10.1128/AAC.02969-15.
31. Zhang Y, Chen XL, Huang AW, Liu SL, Liu WJ, Zhang N, Lu XZ. 2016. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect 5:e27. https://doi.org/10.1038/emi.2016.22.
32. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. 2003. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37:745-751. https://doi.org/10.1086/377200.
33. Lodise TP, Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomae-stro B, McGregor JC. 2007. Predictors of30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51:3510-3515. https://doi.org/10.1128/AAC.00338-07.
34. Weiss SL, Fitzgerald JC, Balamuth F, Alpern ER, Lavelle J, Chilutti M, Grundmeier R, Nadkarni VM, Thomas NJ. 2014. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med 42:2409-2417. https://doi.org/10.1097/CCM.0000000000000509.